本研究旨在利用急性髓性白血病 (AML) 患者骨髓 (BM) 抽吸物中的细胞外囊泡 (EV) 建立具有临床意义的 microRNA (miRNA) 组，并鉴定在 AML 中与这些 EV 衍生的 miRNA 相互作用的基因. 骨髓抽吸物是从 32 名 AML 诊断时的患者身上收集的。使用尺寸排阻色谱法分离 EV。所有样本中总共鉴定出 965 个 EV 衍生的 miRNA。我们分析了有利（n = 10）和不利（n = 22）风险组的这些 EV 衍生 miRNA 的表达水平；我们在非有利风险组中鉴定出 32 个差异表达的 EV 衍生 miRNA。使用癌症基因组图谱 (TCGA) 数据库中 AML 患者的信息分析了这些 miRNA 与风险分层和患者生存的相关性。在非有利风险组中表达下调的 miRNA 中，hsa-miR-181b 和 hsa-miR-143 与不利风险和较短的总生存期相关。对于非有利风险组中表达上调的 miRNA，hsa-miR-188 和 hsa-miR-501 与非有利风险相关，并且可以预测较差的生存率。通过使用 TCGA 数据库对 EV 衍生的 miRNA-mRNA 网络进行分析，我们鉴定了 21 种可能成为潜在不良预后生物标志物的 mRNA。总体而言，我们的研究结果表明，EV 衍生的 miRNA 可以作为 AML 风险分层和预后的生物标志物。此外，这些 EV 衍生的基于 miRNA 的生物信息学分析可以帮助有效识别具有生物标志物潜力的 mRNA，类似于之前基于细胞的方法。版权所有：© 2024 Kang 等人。这是一篇根据知识共享署名许可条款分发的开放获取文章，允许在任何媒体上不受限制地使用、分发和复制，前提是注明原始作者和来源。

This study aimed to establish clinically significant microRNA (miRNA) sets using extracellular vesicles (EVs) from bone marrow (BM) aspirates of patients with acute myelogenous leukemia (AML), and to identify the genes that interact with these EV-derived miRNAs in AML.BM aspirates were collected from 32 patients with AML at the time of AML diagnosis. EVs were isolated using size-exclusion chromatography. A total of 965 EV-derived miRNAs were identified in all the samples.We analyzed the expression levels of these EV-derived miRNAs of the favorable (n = 10) and non-favorable (n = 22) risk groups; we identified 32 differentially expressed EV-derived miRNAs in the non-favorable risk group. The correlation of these miRNAs with risk stratification and patient survival was analyzed using the information of patients with AML from The Cancer Genome Atlas (TCGA) database. Of the miRNAs with downregulated expression in the non-favorable risk group, hsa-miR-181b and hsa-miR-143 were correlated with non-favorable risk and short overall survival. Regarding the miRNAs with upregulated expression in the non-favorable risk group, hsa-miR-188 and hsa-miR-501 were correlated with non-favorable risk and could predict poor survival. Through EV-derived miRNAs-mRNA network analysis using TCGA database, we identified 21 mRNAs that could be potential poor prognosis biomarkers.Overall, our findings revealed that EV-derived miRNAs can serve as biomarkers for risk stratification and prognosis in AML. In addition, these EV-derived miRNA-based bioinformatic analyses could help efficiently identify mRNAs with biomarker potential, similar to the previous cell-based approach.Copyright: © 2024 Kang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.